NASDAQ:KODK

Kodiak Sciences Falls Before Holiday Pause With Eyes on Drug Update
····

Kodiak Sciences Falls Before Holiday Pause With Eyes on Drug Update

Kodiak Sciences shares fell 3.2% to $36.23 Friday, ending a volatile week ahead of a three-day U.S. market closure. No new company updates were posted; investors await late-stage trial results for Zenkuda, Kodiak’s experimental retina drug. The stock remains above pre-March levels, after Zenkuda met a key Phase 3 goal for diabetic retinopathy. One-year data from a wet AMD trial is expected in September.
May 22, 2026

Stock Market Today

  • J Sainsbury Investment Narrative Shifts Amid Mixed Analyst Views
    May 29, 2026, 10:46 PM EDT. The investment narrative for J Sainsbury (LSE:SBRY) is evolving with mixed analyst opinions. Fair value estimates slightly decreased from £3.55 to £3.48 per share amid varying target adjustments. Deutsche Bank and JPMorgan remain bullish, raising price targets to around £3.60 and £3.45, respectively, indicating potential upside. Conversely, Morgan Stanley, Goldman Sachs, and Citi adopt more cautious stances, highlighting competitive challenges. Sainsbury announced a £300 million share buyback plan through February 2027, supporting shareholder value. Adjustments include a slightly higher revenue growth forecast at 2.76%, a marginally lower net profit margin of 1.59%, and a discount rate revising to 9.00%. Investors can track developments via Simply Wall St's community and watchlists to gauge shifting market perspectives on the UK grocer's stock.